Doctors have for the first time released details of their spending on a major clinical trial, demonstrating that the true cost of developing a medicine may be far less than the billions of dollars claimed by the pharmaceutical industry.
BigHat Biosciences Enters Into Strategic Collaboration to Leverage Machine Learning in Antibody Discovery & Design
AbbVie and BigHat Biosciences Announce Research Collaboration
While other biotechs are culling staff and programs to stay afloat, BigHat Biosciences has remained dry under its ever-expanding umbrella, announcing a multiprotein deal with Merck & Co. while growing its team 30% since the summer.
BigHat Biosciences just capped off an $75 million series B to design safer, more effective antibody therapies, with Big Pharmas Amgen and Bristol Myers Squibb both joining the round as new investors.
SAN MATEO, Calif.--(BUSINESS WIRE)--BigHat Biosciences, a biotechnology company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, today announced it has raised a $75 million Series B funding round, led by Section 32, with participation from new investors Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital, among others. The investment brings BigHat’s total funding to date to $100 million. Prior investors Andreessen Horowitz, 8VC, and AME Cloud Ventures also contributed to this round, which will be used to scale the capacity of MillinerTM, an integrated AI/ML- wet lab platform, advance therapeutic programs toward human clinical trials, aggressively hire drug discovery and development talent and to accelerate strategic collaborations with flagship partners.
SAN MATEO, Calif.--(BUSINESS WIRE)--BigHat Biosciences, Inc., a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, today announced the successful completion of the first stage of a previously undisclosed research collaboration and licensing agreement with Amgen applying BigHat’s platform for multi-objective optimization of a next-generation antibody.